DOTMATICS
30.3.2017 09:02:08 CEST | Business Wire | Press release
Dotmatics , a leading provider of scientific informatics solutions and services, today announced Reaction Workflows (RW), a major new application within the Dotmatics 5.1 suite that lets scientists quickly and easily define and execute common cheminformatics tasks, such as library enumeration, structure normalization and compound profiling, in a graphical workflow environment.
RW, part of the integrated Dotmatics 5.1 informatics suite, allows scientists to produce an easily understandable graphical record for sharing scientific best practices and knowledge retention within an organization. Scientists can develop workflows quickly and easily using an intuitive, drag-and-drop web-based interface without programming or scripting experience.
“Reaction Workflows provides the ability for any chemist within a company to easily perform an important set of cheminformatics tasks,” said Dotmatics’ Director and Chief Scientific Officer Mike Hartshorn, Ph.D. “This application complements the enhanced user experience and increased accessibility in our 5.1 platform suite by allowing scientists to perform their own ad-hoc analysis without the need for additional resources. This removes a common and time-consuming roadblock to meeting their goals.”
Intuitive User Interface
Within RW, workflows are built from nodes that provide inputs and outputs or perform actions. Using the drag-and-drop interface, the nodes are joined together to define a data process to perform. This makes designing or modifying workflows significantly faster and less prone to error than manual development without requiring specialized technical skills.
Immediate Productivity
The application includes a variety of chemically intelligent nodes including ones to perform reaction-, scaffold-, and transform-based enumeration. Nodes for performing structure normalization, property calculation, substructure annotation and filtering are also available. Other nodes read and write chemical structures and visualize the results or send them to Dotmatics Vortex for further analysis. The ability to perform the different types of enumeration in combination with property/structure annotation and filtering means it can be used for many common medicinal chemistry use cases. Nodes come populated with external content to ensure that chemists can be immediately productive. For example:
- The reaction node provides an extensive list of pre-built chemical reactions that are commonly used in synthetic and medicinal chemistry.
- The transform node provides a set of structural changes that are performed in medicinal chemistry to alter structures. Further reactions, transforms or scaffolds can be added easily.
- The reagent node is preconfigured with common sets of chemical reagents from Dotmatics Chemselector .
Chemistry teams or individuals can add and share additional reactions and other content to these stores based on proprietary corporate knowledge.
Address Wide Variety of Tasks
Reaction Workflows is a highly flexible application where multiple cheminformatics nodes can be joined together to build workflows quickly and thoroughly. Typical use cases include reaction-based enumeration, Markush-based enumeration, virtual library-enumeration, and profiling and structure normalization for registration. The application also allows scientists to create workflows for lead hopping, filtering and profiling sets of structures by properties and substructures. It even allows for the creation of workflows that address the important but mundane task of chemistry file cleanup, which allows cheminformaticians to automate the correction of errors and inconsistencies in data and structure files, prior to their use in design.
Integrates with Dotmatics Applications
RW is integrated into the Dotmatics Suite. Browser hit lists, for example, sets of reagents, can be used as input into the reagents node. A Vortex node can be inserted into a workflow so that the results of an enumeration and an interactive selection in Vortex can provide input to the next node in the workflow.
An Introducing Dotmatics Reaction Workflows webinar will be held Thursday, April 6, 2017, from 10:30-11:30 am Eastern Time. A What’s New in Dotmatics 5. 1 webinar will be held May 9, 2017, from 10:30-11:30 am Eastern Time. Dotmatics presenters Phil Mounteney, head of application science, North America and Gianpaolo Bravi, senior scientist and one of the lead developers of RW, will provide a product overview and lead a demonstration. To register for the April 6 webinar click here . To register for the May 9 webinar click here . A video of 5.1 including Reaction Workflows is available here .
About Dotmatics:
Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information visit dotmatics.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005447/en/
Contact:
Dotmatics
Marla Kertzman, +1 209-852-9027
pr@dotmatics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
